Humoral immune response after CD40-CD40L blockade
| Treatment . | Anti-fVIII antibody titer, μg/mL . | |||
|---|---|---|---|---|
| End of treatment . | Challenge with fVIII (days after treatment) . | |||
| 50 . | 100 . | 150 . | ||
| Hamster IgG plus fVIII | 1.3 | 66 | Died | — |
| 14 | 110 | Died | — | |
| 15 | Died | — | — | |
| 50 | 232 | 661 | 474 | |
| 145 | 103 | 180 | 185 | |
| fVIII alone | 3.6 | 77 | 104 | 165 |
| 4.3 | 83 | 168 | 65 | |
| 12 | 134 | 123 | 300 | |
| 19 | 77 | 51 | 120 | |
| 53 | 166 | 175 | 250 | |
| Anti-CD40L + fVIII (nontolerant) | 0.02 | 0.96 | 14.8 | 182 |
| 0.03 | 0.2 | 4.2 | 180 | |
| 0.05 | 0.9 | 36 | 185 | |
| 0.1 | 0.36 | 1.2 | 20 | |
| 0.15 | 60 | 258 | 300 | |
| 0.15 | 53 | 617 | 550 | |
| 0.39 | 4.3 | 186 | 276 | |
| 0.65 | 19 | 165 | 116 | |
| 0.9 | 0.08 | 117 | 338 | |
| 1.5 | 5.8 | 25 | 150 | |
| Anti-CD40L + fVIII (tolerant) | 0.02 | 0.01 | 0.01 | 0.05 |
| 0.05 | 0.06 | 0.08 | 0.05 | |
| 0.05 | 0.01 | 0.05 | 0.02 | |
| 0.05 | 0.09 | 0.08 | 0.04 | |
| 0.06 | 0.04 | 0.05 | 0.05 | |
| 0.08 | 0.04 | 0.07 | 0.05 | |
| 0.09 | 0.02 | 0.06 | 0.04 | |
| 0.1 | 0.15 | 0.11 | 0.5 | |
| 0.1 | 0.04 | 0.48 | 0.85 | |
| 0.12 | 0.1 | 0.05 | 0.08 | |
| 0.15 | 0.05 | 0.18 | 0.22 | |
| 0.35 | 0.06 | 0.04 | 0.16 | |
| Treatment . | Anti-fVIII antibody titer, μg/mL . | |||
|---|---|---|---|---|
| End of treatment . | Challenge with fVIII (days after treatment) . | |||
| 50 . | 100 . | 150 . | ||
| Hamster IgG plus fVIII | 1.3 | 66 | Died | — |
| 14 | 110 | Died | — | |
| 15 | Died | — | — | |
| 50 | 232 | 661 | 474 | |
| 145 | 103 | 180 | 185 | |
| fVIII alone | 3.6 | 77 | 104 | 165 |
| 4.3 | 83 | 168 | 65 | |
| 12 | 134 | 123 | 300 | |
| 19 | 77 | 51 | 120 | |
| 53 | 166 | 175 | 250 | |
| Anti-CD40L + fVIII (nontolerant) | 0.02 | 0.96 | 14.8 | 182 |
| 0.03 | 0.2 | 4.2 | 180 | |
| 0.05 | 0.9 | 36 | 185 | |
| 0.1 | 0.36 | 1.2 | 20 | |
| 0.15 | 60 | 258 | 300 | |
| 0.15 | 53 | 617 | 550 | |
| 0.39 | 4.3 | 186 | 276 | |
| 0.65 | 19 | 165 | 116 | |
| 0.9 | 0.08 | 117 | 338 | |
| 1.5 | 5.8 | 25 | 150 | |
| Anti-CD40L + fVIII (tolerant) | 0.02 | 0.01 | 0.01 | 0.05 |
| 0.05 | 0.06 | 0.08 | 0.05 | |
| 0.05 | 0.01 | 0.05 | 0.02 | |
| 0.05 | 0.09 | 0.08 | 0.04 | |
| 0.06 | 0.04 | 0.05 | 0.05 | |
| 0.08 | 0.04 | 0.07 | 0.05 | |
| 0.09 | 0.02 | 0.06 | 0.04 | |
| 0.1 | 0.15 | 0.11 | 0.5 | |
| 0.1 | 0.04 | 0.48 | 0.85 | |
| 0.12 | 0.1 | 0.05 | 0.08 | |
| 0.15 | 0.05 | 0.18 | 0.22 | |
| 0.35 | 0.06 | 0.04 | 0.16 | |
Mice were injected with hamster IgG plus fVIII, fVIII alone, or with anti-CD40L Ab plus fVIII (treatment); they were further challenged with 0.2 μg fVIII 3 times after the treatment. Anti-fVIII Ab titers were determined by ELISA.